The Biology of HPV+ Cancer, Engineered into a Blood Test.
A Rising Challenge in Oncology.
The incidence of HPV-driven head & neck and anal cancer has been rising for decades. Even with successful treatment, recurrence is a real risk: Up to 25% of HPV+ head & neck cancer patients and up to 30% of HPV+ anal cancer patients may experience recurrence. But the surveillance tools available to detect that recurrence have not kept pace with what we know about the biology driving these cancers.
Meeting the Challenge: The NavDx® Test.
The NavDx® test is the first and most clinically validated liquid biopsy test for HPV+ cancers and the direct result of Naveris’s singular focus on HPV+ cancer biology. With a simple blood draw, the NavDx test enables earlier detection of cancer recurrence, real-time assessment of treatment response, and confirmatory diagnosis when tissue biopsy is inconclusive or unavailable.
The NavDx test is backed by 47 peer-reviewed publications from 44 independent studies and more than 120,000+ tests performed in clinical practice. It is covered by Medicare for post-treatment surveillance of HPV+ oropharyngeal and HPV+ anal squamous cell carcinoma, and by a growing number of commercial insurance plans.
*A pre-treatment test is not required to use the NavDx test at other points in the care journey. Monitoring with the NavDx test can be started at any time.
P R O V I D E R S
Know earlier. Act sooner.
Clinical evidence, ordering information, and the full NavDx evidence base for healthcare providers.
P A T I E N T S
Know more. Worry less.
What NavDx testing means for your care and how to talk to your doctor about it.
Innovation in Development, A Leader in Testing.
Naveris® Inc. is a molecular diagnostics company developing and commercializing novel liquid biopsies to enhance the early detection and clinical management of viral-associated cancers. Our highly sensitive tests use our proprietary technology to capture and analyze cancer-associated HPV DNA in blood plasma and offer greater sensitivity compared to existing circulating tumor DNA (ctDNA) tests.